Mental Health Clinics in Telford, PA Accepting Medicare
3 Mental Health Clinics found. Showing 1 - 3
 Dcs Applied Behavior Analysis, Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 240 Winding Way, Telford, PA 18969 Phone: 610-715-3240 Fax: 801-697-5403 |
Holcomb Behavioral Health Systems Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 960 Long Mill Rd, Telford, PA 18969 Phone: 610-363-1488 |
Armstrong Counseling & Consulting Corporation Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1 Carousel Dr, Telford, PA 18969 Phone: 215-264-5449 |
News Archive
Comparative silence between firing spikes of neurons reveals what they are really up to
It's the comparative silence between the firing spikes of neurons that tells what they are really up to, scientists report.
New drug successfully lowers levels of toxic protein that causes Huntington disease
An international clinical trial has found that a new drug for Huntington disease is safe, and that treatment with the drug successfully lowers levels of the abnormal protein that causes the debilitating disease in patients.
Minn. Gov. decides to not expand Medicaid early; Ohio wrestles with increased Medicaid costs in overhaul; Kansas officials worry about 25% cut in health policy operating budget
"As expected, Gov. Tim Pawlenty has declined the opportunity for Minnesota to get an early shot at expanding Medicaid eligibility. The federal health plan calls for all states to expand Medicaid eligibility to low-income adults without children in 2014, but Minnesota was among a few states offered a chance to do it earlier." The legislature, however, passed a measure that would allow Pawlenty's successor next year to reverse his ruling (Kimball, 6/22).
ThromboGenics completes enrollment in second microplasmin Phase III trial
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
Depomed reports financial results for third quarter 2013
Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.
› Verified 3 days ago